Review discusses advances in radiation and systemic therapies for small cell lung cancer, indicating improved outcomes for various disease stages.
Small cell lung cancer (SCLC) is a highly aggressive malignancy that is characterised by rapid proliferation and early metastatic dissemination. This review outlines the advances in management strategies for very limited-stage (VLS-SCLC), limited-stage (LS-SCLC) and extensive-stage (ES-SCLC) disease, with emphasis on recent advances in thoracic radiation therapy (TRT) techniques and dose fractionation, as well as the integration of systemic treatments including immuno-oncological therapies (IO). Given the high incidence of cerebral metastases, contemporary cranial radiation techniques will be examined, including hippocampal avoidance (HA) and stereotactic radiosurgery (SRS), as well as the evolving role of prophylactic cranial irradiation (PCI) in the setting of routine magnetic resonance imaging (MRI) surveillance.
No takes yet. Share an insight, caveat, or question.
Liefman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: